Effectiveness of Chemo-Immunotherapy (CIT) and Novel Therapies in Second or Later Line of Therapy (2L+) for Patients with Relapsed/Refractory (R/R) Aggressive Large B-Cell Lymphoma (LBCL)

被引：1
|
作者：
Nastoupil, Loretta J. [1 ]
Andersen, Clark R. [1 ]
Ayers, Amy [1 ]
Wang, Yucai [2 ]
Habermann, Thomas M. [2 ]
Chihara, Dai [1 ]
Kahl, Brad S. [3 ]
Link, Brian K. [4 ]
Cohen, Jonathon B. [5 ]
Martin, Peter [6 ]
Lossos, Izidore S. [7 ]
Casulo, Carla [8 ]
Lin, Ruitao [1 ]
Li, Ziyi [1 ]
Larson, Melissa C. [2 ]
Maurer, Matthew J. [2 ]
Huynh, Lynn [9 ]
Gao, Chi [9 ]
Ramasubramanian, Ramya [9 ]
Sheng, Mei [9 ]
Mutebi, Alex [10 ]
Wang, Tongsheng [10 ]
Jun, Monika [10 ]
Wang, Anthony [11 ]
Kamalakar, Rajesh [11 ]
Kalsekar, Anupama [10 ]
Cerhan, James R. [2 ]
Flowers, Christopher R. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Mayo Clin, Rochester, MN USA
[3] Washington Univ, Sch Med St Louis, St Louis, MO USA
[4] Univ Iowa, Carver Coll Med, Iowa City, IA USA
[5] Emory Univ, Atlanta, GA USA
[6] Weill Cornell Med Coll, New York, NY USA
[7] Univ Miami Hlth Syst, Miami, FL USA
[8] Univ Rochester, Med Ctr, Rochester, NY USA
[9] Anal Grp Inc, Boston, MA USA
[10] Genmab, Princeton, NJ USA
[11] AbbVie Inc, Chicago, IL USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-174497
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [41] CLINICAL PREDICTORS OF AXICABTAGENE CILOLEUCEL (AXI-CEL) THERAPY FOR RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL): A SYSTEMATIC LITERATURE REVIEW (SLR) AND META-ANALYSIS
    Sanderson, R.
    Munoz, J.
    Wang, Y.
    Kanters, S.
    Limbrick-Oldfield, E.
    Miao, H.
    Spooner, C.
    Baro, E.
    Xu, H.
    Jacobson, C.
    VALUE IN HEALTH, 2022, 25 (12) : S47 - S48
  • [42] Real-world outcomes of patients with relapsed/refractory large B-cell lymphoma receiving second-line therapy in England
    Fox, Christopher P.
    Townsend, William
    Gribben, John G.
    Menne, Tobias
    Kalakonda, Nagesh
    Williams, Paula
    Toron, Farah
    Tyas, Emma
    Cooper, Miranda
    Rickards, Joshua
    Radford, John
    EJHAEM, 2024, 5 (05): : 992 - 997
  • [43] Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Real-World Practice Patterns and Outcomes
    Khurana, Arushi
    Bailey, Megumi
    Iqbal, Madiha
    Bansal, Radhika
    Lee, Catherine J.
    Hunter, Bradley
    Lunning, Matthew A.
    Jaglowski, Samantha
    Jain, Michael D.
    Dahiya, Saurabh
    Bachanova, Veronika
    Farooq, Umar
    Ahmed, Sairah
    Hill, Brian T.
    Munoz, Javier L.
    Patel, Krish
    Oluwole, Olalekan O.
    Lin, Yi
    BLOOD, 2022, 140 : 4657 - 4660
  • [44] Interim evaluation of a targeted radiotherapeutic, CLR 131, in relapsed/refractory diffuse large B-cell lymphoma patients (R/R DLBCL)
    Longcor, J.
    Oliver, K.
    Friend, J.
    Callandar, N.
    ANNALS OF ONCOLOGY, 2019, 30 : 435 - 435
  • [45] Management of Canadian Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the Real-World
    Peters, Anthea
    Nowakowski, Grzegorz S.
    Dabas, Rosy
    Amoloja, Theresa
    Xue, Zhenyi
    Koch, Caroline
    Waltl, Eva E.
    Fleury, Isabelle
    BLOOD, 2022, 140 : 3811 - 3813
  • [46] Clinical pharmacology of tisagenlecleucel (CTL019) in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)
    Awasthi, Rakesh
    Tam, Constantine S.
    Jaeger, Ulrich
    Jaglowski, Samantha
    Foley, Stephen Ronan
    van Besien, Koen
    Wagner-Johnston, Nina D.
    Kersten, Maria Jose
    Schuster, Stephen J.
    Salles, Gilles
    Maziarz, Richard T.
    Anak, Ozlem
    Pacaud, Lida Bubuteishvili
    Gazi, Lucien
    Waldron, Edward
    Hamilton, Jason
    Pruteanu, Iulian
    Tai, Feng
    Mueller, Karen Thudium
    Waller, Edmund K.
    CANCER RESEARCH, 2018, 78 (13)
  • [47] Interviews of Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Lisocabtagene Maraleucel (liso-cel) Trials on Their Treatment Experience for 3 Months after Infusion
    Siddiqi, Tanya
    Jaeger, Ulrich
    Moshkovich, Olga
    Braverman, Julia
    Liu, Fei Fei
    Lanar, Sally
    Miera, Matthew
    Shah, Selam
    Devlen, Jennifer
    Salles, Gilles
    BLOOD, 2021, 138
  • [48] Qualitative Analysis of the Treatment Experience and Well-Being of Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Trials of Lisocabtagene Maraleucel (liso-cel) during the Initial Stages of Therapy
    Siddiqi, Tanya
    Jaeger, Ulrich
    Moshkovich, Olga
    Devlen, Jennifer
    Miera, Matthew
    Williams, Agnes
    Hasskarl, Jens
    Liu, Fei Fei
    Braverman, Julia
    Salles, Gilles
    BLOOD, 2020, 136
  • [49] Immunogenicity of tisagenlecleucel in relapsed/ refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) patients.
    Mueller, Karen Thudium
    Grupp, Stephan A.
    Maude, Shannon L.
    Levine, John E.
    Pulsipher, Michael
    Boyer, Michael W.
    August, Keith Jason
    Myers, Gary Douglas
    Awasthi, Rakesh
    Waldron, Edward K.
    Bubuteishvili-Pacaud, Lida
    Taran, Tanya
    Cota, Mariana
    Tam, Constantine Si Lun
    Jager, Ulrich
    Foley, Ronan
    Borchmann, Peter
    Schuster, Stephen J.
    Waller, Edmund K.
    Laetsch, Theodore Willis
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [50] Costs of Postinfusion Monitoring By Site of Care for Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Who Received Third-Line or Later Treatment with Lisocabtagene Maraleucel (liso-cel) in the Transcend NHL 001 and Outreach Trials
    Palomba, M. Lia
    Jun, Monika P.
    Garcia, Jacob
    Lymp, James
    McGarvey, November
    Gitlin, Matthew
    Pelletier, Corey
    Nguyen, Andy
    BLOOD, 2020, 136
12345